Information between 30th August 2025 - 9th September 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
2 Sep 2025 - English Devolution and Community Empowerment Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 352 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 365 Noes - 164 |
|
2 Sep 2025 - English Devolution and Community Empowerment Bill - View Vote Context Bambos Charalambous voted No - in line with the party majority and in line with the House One of 352 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 167 Noes - 367 |
|
3 Sep 2025 - Property Taxes - View Vote Context Bambos Charalambous voted No - in line with the party majority and in line with the House One of 322 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 98 Noes - 335 |
|
3 Sep 2025 - Hospitality Sector - View Vote Context Bambos Charalambous voted No - in line with the party majority and in line with the House One of 325 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 158 Noes - 334 |
|
4 Sep 2025 - House of Lords (Hereditary Peers) Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 261 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 338 Noes - 74 |
|
4 Sep 2025 - House of Lords (Hereditary Peers) Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 262 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 336 Noes - 77 |
|
4 Sep 2025 - House of Lords (Hereditary Peers) Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 265 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 331 Noes - 73 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 315 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 335 Noes - 160 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 316 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 325 Noes - 171 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 317 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 404 Noes - 98 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 317 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 401 Noes - 96 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 314 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 336 Noes - 158 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 319 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 402 Noes - 97 |
|
8 Sep 2025 - Renters’ Rights Bill - View Vote Context Bambos Charalambous voted Aye - in line with the party majority and in line with the House One of 317 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 398 Noes - 93 |
| Speeches |
|---|
|
Bambos Charalambous speeches from: Procedure Committee
Bambos Charalambous contributed 1 speech (95 words) Thursday 4th September 2025 - Westminster Hall |
| Written Answers |
|---|
|
Motor Neurone Disease: Medical Treatments
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green) Monday 1st September 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to innovative treatments for people with SOD1 motor neurone disease. Answered by Karin Smyth - Minister of State (Department of Health and Social Care) The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the Naitonal Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims, wherever possible, to issue guidance close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance. NICE has selected tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations as a topic for guidance development through its Highly Specialised Technology (HST) programme. The HST programme appraises medicines for the treatment of very rare, and often very severe diseases, and evaluates whether they can be considered a clinically and cost-effective use of NHS resources. NICE is working with the company to confirm timelines for this evaluation. |